M

Madrigal Pharmaceuticals
D

MDGL

315.49
USD
-11.63
(-3.55%)
مغلق
حجم التداول
39,460
الربح لكل سهم
-12
العائد الربحي
-
P/E
-18
حجم السوق
7,004,913,438
أصول ذات صلة
E
EXEL
0.700
(1.80%)
39.600 USD
INSM
INSM
-0.320
(-0.44%)
72.320 USD
K
KPTI
0.70000
(10.37%)
7.45000 USD
المزيد
الأخبار المقالات

العنوان: Madrigal Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.